NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal (STA)

Ruxolitinib for disease-related splenomegaly or symptoms in adults with myelofibrosis (review of TA289) – [ID831]

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Company • Novartis Pharmaceuticals (ruxolitinib) Patient/carer groups • Leukaemia CARE Professional groups • Association of Cancer Physicians • British Society for Haematology • Cancer Research UK • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists Others • Department of Health • NHS England • NHS Hammersmith and Fulham CCG • NHS South Norfolk CCG • Welsh Government	General • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland Comparator companies • Alan Pharmaceuticals (thalidomide)**(Confidentiality agreement not signed, not participating)** • Bristol-Myers Squibb (hydroxycarbamide) **(Confidentiality agreement not signed, not participating)** • Celgene (lenalidomide, thalidomide)**(Confidentiality agreement not signed, not participating)** • Medac UK (hydroxycarbamide) **(Confidentiality agreement not signed, not participating)** • Nordic (hydoxycarbamide) **(Confidentiality agreement not signed, not participating)** Relevant research groups • Institute of Cancer Research • National Cancer Research Institute Evidence Review Group • NHS Centre for Reviews & Dissemination and Centre for Health Economics - York • National Institute for Health Research Health Technology Assessment Programme

	Associated Guideline Groups • National Collaborating Centre for Cancer Associated Public Health Groups • None

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology are invited to prepare a submission dossier, can respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical specialists and/or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies;
Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary.

All non- company commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the company evidence submission to the Institute.

[1]Non-company consultees are invited to submit statements relevant to the group they are representing.